Clinical Trial Update: A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II study of BYL719 (alpelisib) with cetuximab in recurrent or metastatic head and neck squamous cell carcinoma was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BYL719 (alpelisib)
• Cetuximab (cetuximab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-05-21